Diagnostic capabilities of circulating microRNA profiles in patients with acute coronary syndrome and stable coronary artery disease

Stonogina D.A.

Sechenov First Moscow State Medical University

ORCID: 0000-0002-1508-4257

Zhelankin A.V.

Federal Research Clinical Center for Physico-Chemical Medicine

ORCID: 0000-0002-3014-2005

Vasiliev S.V.

Sechenov First Moscow State Medical University

ORCID: 0000-0003-4845-5402

Generozov E.V.

Federal Research Clinical Center for Physico-Chemical Medicine

ORCID: 0000-0002-6314-4883

Akselrod A.S.

Sechenov First Moscow State Medical University

ORCID: 0000-0003-3417-794X

Diagnostic capabilities of circulating microRNA profiles in patients with acute coronary syndrome and stable coronary artery disease

Authors:

Stonogina D.A., Zhelankin A.V., Vasiliev S.V., Generozov E.V., Akselrod A.S.

More about the authors

Journal: Russian Journal of Cardiology and Cardiovascular Surgery. 2024;17(2): 125‑132

DOI: 10.17116/kardio202417021125

Downloaded: 1

Contact the author

Table of contents

To cite this article:

Stonogina DA, Zhelankin AV, Vasiliev SV, Generozov EV, Akselrod AS. Diagnostic capabilities of circulating microRNA profiles in patients with acute coronary syndrome and stable coronary artery disease. Russian Journal of Cardiology and Cardiovascular Surgery. 2024;17(2):125‑132. (In Russ.)
https://doi.org/10.17116/kardio202417021125

Подписка 2025 (Russian Journal of Cardiology and Cardiovascular Surgery)

Close metadata

OBJECTIVE

To analyze serum circulating microRNAs (c-microRNAs) in patients with various forms of coronary artery disease (CAD) considering basic pre-analytical requirements necessary for analysis of c-microRNAs.

MATERIAL AND METHODS

Quantitative PCR was used to analyze serum c-microRNA (miR-21-5p, miR-155-5p, miR-17-5p, miR-92a-3p, miR-126-3p, miR-145-5p, miR-146a -5p and miR-375-3p) potentially associated with atherosclerosis.

RESULTS

We assessed 136 men and women and found that serum miR-146a-5p and miR-21-5p were significantly higher in patients with acute coronary syndrome (ACS). Serum miR-17-5p was lower in patients with ACS and stable CAD compared to healthy individuals and patients with arterial hypertension without CAD. In patients with ACS, there were no differences in serum microRNAs among patients with myocardial infarction and unstable angina. In addition, serum microRNAs in patients with myocardial infarction with and without ST segment elevation did not show significant differences.

CONCLUSION

Elevated serum miR-21-5p and miR-146a-5p can be considered as a significant biomarker of ACS, while serum miR-17-5p should be regarded as a general biomarker of CAD.

Keywords:

miRNA

coronary artery disease

acute coronary syndrome

circulating biomarkers

Authors:

Stonogina D.A.

Sechenov First Moscow State Medical University

ORCID: 0000-0002-1508-4257

Zhelankin A.V.

Federal Research Clinical Center for Physico-Chemical Medicine

ORCID: 0000-0002-3014-2005

Vasiliev S.V.

Sechenov First Moscow State Medical University

ORCID: 0000-0003-4845-5402

Generozov E.V.

Federal Research Clinical Center for Physico-Chemical Medicine

ORCID: 0000-0002-6314-4883

Akselrod A.S.

Sechenov First Moscow State Medical University

ORCID: 0000-0003-3417-794X

Received:

29.12.2023

Accepted:

10.01.2024

List of references:

Wang J, Tan G-J, Han L-N, et al. Novel Biomarkers for Cardiovascular Risk Prediction. J Geriatr Cardiol. 2017;14:135-150.
Korley FK, Jaffe AS. Preparing the United States for High-Sensitivity Cardiac Troponin Assays. J Am Coll Cardiol. 2013;61:1753-1758.
Bronze-da-Rocha E. MicroRNAs Expression Profiles in Cardiovascular Diseases. Biomed Res Int. 2014;2014:958408.
Ahlin F, Arfvidsson J, Vargas KG, et al. MicroRNAs as Circulating Biomarkers in Acute Coronary Syndromes: A Review. Vasc Pharmacol. 2016;81:15-21.
Feinberg MW, Moore KJ. MicroRNA Regulation of Atherosclerosis. Circ Res. 2016;118:703-720.
Liu Y, Li Q, Hosen MR, et al. Atherosclerotic Conditions Promote the Packaging of Functional MicroRNA-92a-3p Into Endothelial Microvesicles. Circ Res. 2019;124:575-587.
Chamorro-Jorganes A, Lee MY, Araldi E, et al. VEGF-Induced Expression of MiR-17-92 Cluster in Endothelial Cells Is Mediated by ERK/ELK1 Activation and Regulates Angiogenesis. Circ Res. 2016;118:38-47.
Bonauer A, Carmona G, Iwasaki M, et al. MicroRNA-92a Controls Angiogenesis and Functional Recovery of Ischemic Tissues in Mice. Science. 2009;324:1710-1713.
Wang S, Aurora AB, Johnson BA, et al. An Endothelial-Specific MicroRNA Governs Vascular Integrity and Angiogenesis. Dev Cell. 2008;15:261-271.
Fish JE, Santoro MM, Morton SU, et al. MiR-126 Regulates Angiogenic Signaling and Vascular Integrity. Dev Cell. 2008;15:272-284.
Labbaye C, Testa U. The Emerging Role of MIR-146A in the Control of Hematopoiesis, Immune Function and Cancer. J Hematol Oncol. 2012;5:13.
Faraoni I, Antonetti FR, Cardone J, Bonmassar E. miR-155 Gene: A Typical Multifunctional MicroRNA. BiochimicaBiophysicaActa BBA Mol. BasisDis. 2009;1792:497-505.
Cheng Y, Zhang C. MicroRNA-21 in Cardiovascular Disease. J Cardiovasc Transl Res. 2010;3:251-255.
Baulina N, Osmak G, Kiselev I, et al. NGS-Identified Circulating MiR-375 as a Potential Regulating Component of Myocardial Infarction Associated Network. J Mol Cell Cardiol. 2018;121:173-179.
Binderup HG, Madsen JS, Heegaard NHH, et al. Quantification of MicroRNA Levels in Plasma — Impact of Preanalytical and Analytical Conditions. PLoS One. 2018;13:e0201069.
Blondal T, Jensby Nielsen S, Baker A, et al. Assessing Sample and MiRNA Profile Quality in Serum and Plasma or Other Biofluids. Methods. 2013;59:S1-S6.
Godoy PM, Bhakta NR, Barczak AJ, et al. Large Differences in Small RNA Composition Between Human Biofluids. Cell Rep. 2018;25:1346-1358.
Max KEA, Bertram K, Akat KM, et al. Human Plasma and Serum Extracellular Small RNA Reference Profiles and Their Clinical Utility. Proc Natl Acad Sci USA. 2018;115:E5334-E5343.
Sunderland N, Skroblin P, Barwari T, et al. MicroRNA Biomarkers and Platelet Reactivity. Circ Res. 2017;120:418-435.
Krammer TL, Mayr M, Hackl M. MicroRNAs as Promising Biomarkers of Platelet Activity in Antiplatelet Therapy Monitoring. Int J Mol Sci. 2020;21:561.
Willeit P, Zampetaki A, Dudek K, et al. Circulating MicroRNAs as Novel Biomarkers for Platelet Activation. Circ Res. 2013;112:595-600.
De Boer HC, van Solingen C, Prins J, et al. Aspirin Treatment Hampers the Use of Plasma MicroRNA-126 as a Biomarker for the Progression of Vascular Disease. Eur Heart J. 2013;34:3451-3457.
Kaur A, Mackin ST, Schlosser K, et al. Systematic Review of MicroRNA Biomarkers in Acute Coronary Syndrome and Stable Coronary Artery Disease. Cardiovasc Res. 2020;116 1113-1124.
D’Alessandra Y, Chiesa M, Carena MC, et al. Differential Role of Circulating MicroRNAs to Track Progression and Pre-Symptomatic Stage of Chronic Heart Failure: A Pilot Study. Biomedicines. 2020;8:597.
Muñoz-San Martín M, Reverter G, Robles-Cedeño R, et al. Analysis of MiRNA Signatures in CSF Identifies Upregulation of MiR-21 and MiR-146a/b in Patients with Multiple Sclerosis and Active Lesions. J Neuroinflammation. 2019;16:220.
Hammad Mahmoud Hammad R, Hamed DHED, Eldosoky MAER, et al. Plasma MicroRNA-21, MicroRNA-146a and IL-13 Expression in Asthmatic Children. InnateImmun. 2018;24:171-179.
Xue S, Liu D, Zhu W, et al. Circulating MiR-17-5p, MiR-126-5p and MiR-145-3p Are Novel Biomarkers for Diagnosis of Acute Myocardial Infarction. Front Physiol. 2019;10:123.
Stephan F, De Salvatore R, Henrik F, et al. Circulating MicroRNAs in Patients With Coronary Artery Disease. Circ Res. 2010; 107:677-684.
Zhelankin AV, Vasiliev SV, Stonogina DA, et al. Elevated Plasma Levels of Circulating Extracellular MiR-320a-3p in Patients with Paroxysmal Atrial Fibrillation. Int J Mol Sci. 2020;21:3485.
D’Alessandra Y, Devanna P, Limana F, et al. Circulating MicroRNAs Are New and Sensitive Biomarkers of Myocardial Infarction. Eur Heart J. 2010;31:2765-2773.

Close metadata